Introduction
Clinical and experimental studies have shown that status epilepticus may induce neuronal damage, especially in the hippocampus. Whether repeated brief seizures can cause such neuronal damage is, however, controversial.
1,2 Markers of brain injury, such as neuron-specific enolase (NSE) or S-100b protein (S-100), have been measured in patients with seizures. Increased levels of NSE have been reported in a subset of epileptic patients. 3 However, in our previous study neither NSE nor S-100 was elevated in serum or cerebrospinal fluid (CSF) after a single tonicclonic seizure in patients with a newly diagnosed seizure disorder. 4 Tau is a microtubule-associated protein with a major role in normal microtubular function in axons. Tau is a phosphoprotein but abnormally high phosphorylation of tau protein decreases its ability to promote microtubular assembly. The equilibrium between phosphorylation and dephosphorylation modulates cytoskeletal stability and axonal morphology. 5 Tau protein is primarily localized in axons, and after brain parenchymal damage its release into CSF may increase. 6 Increased levels of CSF total tau (T-tau) and especially phosphorylated tau (P-tau) are frequently found in patients with Alzheimer's disease (AD) but also in patients with various neurological diseases, such as traumatic brain injury, 7 acute ischemic stroke, 8 and viral encephalitis, suggesting that Ttau CSF levels reflect the extent of axonal damage and neuronal degeneration. 9,10 CSF tau levels are very high in patients with
Creuzfeldt-Jakob disease.
11
To our knowledge, tau levels have not been previously measured after epileptic seizures. We hypothesized that CSF tau levels may be a marker of neuronal damage in patients suffering from epileptic seizures. Therefore, we studied T-tau and P-tau levels and P-tau/T-tau ratio in CSF after epileptic seizures due to various etiologies.
Materials and methods
The study was performed at the Emergency Department of Neurology, Tampere University Hospital, Finland. A total of 54 patients with tonic-clonic or partial secondarily generalized seizures were included in the study. The patients had either single or recurrent seizures (the median number of seizures was 1.5). Seizure 18 (2009) [474] [475] [476] [477] Purpose: Whether repeated brief seizures can cause neuronal damage is controversial. Cerebrospinal fluid (CSF) total tau (T-tau) and phosphorylated tau (P-tau) measurements have been suggested for the diagnosis of Alzheimer's disease, and T-tau may also be a marker of axonal damage and neuronal degeneration. We studied T-tau and P-tau levels and P-tau/T-tau ratio in CSF after epileptic seizures in order to determine whether they are increased after seizures. Methods: A total of 54 patients with tonic-clonic or partial secondarily generalized seizures due to various etiologies were studied and CSF obtained within 48 h after the seizure. Results: There were no statistical differences in the levels of T-tau (p = 0.09, ANOVA) or P-tau (p = 0.60) between different etiologic groups or controls. No patients with epilepsy of unknown origin had abnormal CSF T-tau whereas 11 patients with acute or remote symptomatic seizures had abnormal T-tau levels and the P-tau/T-tau ratio showed significant differences between the groups and controls (p = 0.003). Conclusions: Epileptic seizures with unknown etiology did not increase CSF tau levels. Abnormal tau levels were associated with either acute or remote symptomatic seizures with known etiology. The presence of elevated CSF tau increases the probability of symptomatic cause in a patient with a seizure.
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Nine patients had status epilepticus. There were 30 male and 24 female patients with a mean age of 48 years (range 16-88 years). All patients were fully informed of the risks and potential benefits of the CSF examination, which was performed to exclude CNS infection. Informed consent to participate in the study was obtained from each subject. The study protocol was approved by the Ethics Committee of Tampere University Hospital. CSF tau increases with age. 12, 13 The reference values for tau have been established for elderly patients (>60 years) in our laboratory. 14 Therefore, we obtained control samples from 31 younger (<60 years) patients with neurological symptoms (e.g. dizziness, headache) on whom lumbar puncture was performed to exclude neurological disease. Clinical examination or imaging studies (computed tomography (CT) or magnetic resonance imaging (MRI) of the head) revealed no pathological findings in control subjects. The mean age in the control group was 40 years (range 15-56 years). The patients were divided into groups based on the underlying etiology of epileptic seizures. The seizures were caused by alcohol withdrawal in group 1 (ALCO, n = 15). In groups 2 and 3 the patients had diagnosis of epilepsy. Group 2 (SYMPT, n = 16) had remote symptomatic epilepsy and in group 3 (EPI, n = 13) the patients had either cryptogenic focal (n = 10) or idiopathic epilepsy (n = 3) with no related findings in brain CT or MRI. The etiology of remote symptomatic epilepsy (group 2) was tumor in the CNS (n = 6), post-stroke or post-traumatic epilepsy (n = 7), Alzheimer's disease (n = 1), multiple sclerosis (n = 1), and post-encephalitic epilepsy (n = 1). In group 4 (ACU, n = 7) seizures were caused by acute systemic illness (sepsis and hyponatremia) or acute CNS disorder (acute brain infarction, encephalitis, necrotizing encephalomyelitis). In addition to these four groups, three patients had only a single seizure of unknown etiology.
CSF sampling and biochemical analyses
The CSF samples were taken within 48 h (mean 14.4 h) after the seizure. The samples were stored at À70 8C prior to analysis. The CSF levels of T-tau and P-tau (181P) were measured by a commercial enzyme-linked immunosorbent assay, ELISA (Innogenetics, Ghent, Belgium) according to the manufacturer's protocol. The ELISA analyses were done blinded to the diagnostic group. Two patients in group 4 (ACU) and two in controls did not have enough CSF for Ptau measurement. P-tau/T-tau ratio was also calculated.
Statistical analysis
Because the parameters were not normally distributed nonparametric methods were used. Kruskal-Wallis ANOVA and Mann-Whitney U-test were used to compare concentrations of T-tau and P-tau. Frequency tables were compared with Pearson Chi-square test (in 2 Â 5 tables, 4 degrees of freedom) and Fisher's exact test (post hoc comparisons in 2 Â 2 tables, 1 degree of freedom) when appropriate. The correlations were calculated using Spearman's correlations. Statistical calculations were carried out using Statistica (ver. Win 5.1D, Statsoft Inc., Tulsa, OK, USA). Findings were considered statistically significant at p-values less than 0.05.
Results
The median T-tau level was 163.1 pg/mL and P-tau 39.6 pg/mL in all patients, and 143.5 pg/mL and 38.1 pg/mL in the controls (Fig. 1) . The median P-tau/T-tau ratio was 0.23 in the patients and 0.26 in the controls. There were no statistical differences in T-tau (p = 0.09, ANOVA) or P-tau (p = 0.6, ANOVA) levels between different etiologic groups and controls ( Table 1 ). The number of seizures, status epilepticus or the time interval between the seizures and CSF sample did not correlate with tau concentrations (r = À0.17 to 0.28, Spearman's correlations).
P-tau/T-tau ratio showed significant differences between the groups and controls (p = 0.003, ANOVA, Table 1 ). The controls differed from groups 1, 2 and 4 (p = 0.010-0.008 Mann-Whitney Utest) but there was no statistical difference between the agematched controls and epilepsy group 3 (p = 0.7).
A concentration of T-tau above 400 pg/mL for patients over 60 years was considered abnormal as established in our laboratory. 14 Previous studies have suggested that the reference values for Fig. 1 . The individual values of total tau (T-tau) and phosphorylated tau (P-tau) and P-tau/T-tau ratio in different patient groups and normal controls. ALCO, alcohol withdrawal; SYMPT, remote symptomatic epilepsy; EPI, cryptogenic focal, or idiopathic epilepsy; ACU, acute systemic or CNS illness. The horizontal lines represent the cutoff value for T-tau and P-tau (>60 years).
younger patients are lower. 12, 13 We used 300 pg/mL as reference value for patients below 60 years. However, we found no differences in the mean levels of CSF T-tau or P-tau between age-matched controls and patients with epilepsy group 3. There was statistical difference in the frequency of abnormal T-tau levels between the groups studied (p = 0.002, Pearson Chisquare). None of the patients with epilepsy of unknown origin (group 3) or the controls had abnormal levels of T-tau. Three patients with a single seizure had also normal levels of T-tau. However, a total of 11 patients (20%) in other groups had abnormal T-tau levels. The characteristics of these patients are shown in Table 2 .
In group 1 (ALCO) 20% had abnormal tau concentrations, and two of them showed also brain atrophy in MRI. In group 2 (SYMPT) tau was abnormal in 31%, and all of them showed brain pathology in MRI; two with brain atrophy, one with old contusion and brain atrophy, one with large basal expansion (pituitary adenoma), and one with hippocampal atrophy after encephalitis. In group 4 (ACU) 43% had abnormal tau concentrations, two patients had acute encephalitis and one had necrotizing encephalomyelitis due to intrathecal cytarabine treatment for Burkitt's lymphoma. The controls differed from groups with either acute or remote symptomatic seizures (groups 1, 2 and 4; p = 0.03-0.003, Fisher's exact test) but not from those with epileptic seizures with unknown etiology (group 3, NS). When groups 2 (SYMPT) and 3 (EPI), i.e. epilepsy without acute illness, were compared, there was also statistical difference in the number of abnormal T-tau (p = 0.04, Fisher's exact test).
Discussion
Our results showed that CSF tau levels were within the normal range in patients with idiopathic or cryptogenic epilepsy, and increased levels were only found in patients with either acute or remote symptomatic seizures.
To our knowledge seizure related changes of CSF tau have not been previously studied in patients with different etiologies of epilepsy. A case report based on a single patient found a transient elevation of CSF tau levels in one patient measured 4 days after the seizure. 15 CSF tau showed an increase at 2-3 days after acute stroke 8, 16 but in traumatic brain damage and brain injury after aortic surgery the increase in tau levels started earlier, during the first day. 7, 17, 18 The time interval between LP and seizure varied (mean 14.4 h) in our patients but no correlation between tau levels and the time interval was observed. Elevated CSF T-tau levels have been consistently found in AD and have been suggested to be useful in differentiating AD from normal ageing and depression. 19 However, an overlap exists with other neurodegenerative disorders or conditions with brain parenchymal damage. 9,20 P-tau is considered to reflect the phosphorylation state of tau, being a more direct marker for AD. Consistent with this, in patients with ischemic stroke CSF T-tau but not P-tau levels were increased and showed correlation with the size of the infarct, indicating that CSF T-tau reflects the degree of neuronal damage. 8, 16 Also in Creuzfeldt-Jakob disease marked elevation of T-tau but not P-tau levels has been reported. 11 In
Kapaki's study sensitivity and specificity of P-tau/T-tau ratio were better in the discrimination of AD versus controls than P-tau alone. 20 The best cutoff level for this ratio was !0.169. Most of our patients with abnormal T-tau levels had quite low P-tau and also low P-tau/T-tau ratio indicating rather non-specific neurodegenerative disorder or axonal damage. CSF T-tau has been studied in alcohol related cognitive disorders (ARCD) in attempt to discriminate AD from other dementias using tau measurements. Tau pathology has been found Table 1 The median values of total tau (T-tau), phosphorylated tau (P-tau), and P-tau/T-tau ratio in different patient groups and controls. in chronic alcoholics with thiamine deficiency and degeneration of nucleus basalis may develop through formation of neurofibrillary tangles. 21 This may account for the higher tau values for the ARCD patients compared with the controls 22 or increased tau levels seen in patients with alcohol dementia. 23 In contrast to this, CSF tau was within normal levels in demented and non-demented alcoholics compared with AD patients and controls. 24 In our patients with alcohol withdrawal seizures (group 1) 20% had elevated T-tau levels, two with known alcoholic encephalopathy. Increased levels of tau have also been reported in patients with cerebral infections. In one study 18% of HIV infected patients had increased CSF tau levels, but of those who had cerebral infections and necrosis elevated tau levels were found in 35%. 25 In Sü ssmuth's study, patients with viral encephalitis and bacterial meningitis with meningoencephalopathic complications had elevated tau levels. 10 The authors suggested that tau may be a marker for parenchymal involvement. Consistent with this, three patients in group 4 (ACU) had abnormal levels of tau, two with acute viral encephalitis, one with necrotizing encephalopathy. Other biomarkers, mainly NSE and S-100, have been used to assess possible brain damage after seizure. Several studies have reported raised serum and CSF NSE levels after brief seizures as well as after status epilepticus, 3, 26 but no postictal elevation of S-100 after single seizures has been observed. 4, 27, 28 However, cisternal S-100 as well as NSE levels ipsilateral to the site of seizure onset were elevated interictally in intractable temporal lobe epilepsy. 29 The reduction of endogenous tau levels protected mice against excitotoxicity in an Alzheimer's disease mouse model, 30 indicating that tau may mediate excitotoxicity. Therefore high CSF tau levels after seizure could mark a poorer prognosis. In this study, the seizures without additional pathology were not associated with high tau levels. Furthermore, the number of seizures or status epilepticus did not correlate with the levels of tau. We conclude that abnormal CSF tau levels may be found in patients with seizures. However, acute seizure itself does not seem to lead to the elevation of CSF tau. The presence of increased CSF tau in a patient with epileptic seizure increases the probability of symptomatic cause.
